Azithromycin and survival in Streptococcus pneumoniae pneumonia: A retrospective study

BMJ Open

Volumn 3, Issue 6, 2013, Pages

  Shorr, Andrew F ^a   Zilberberg, Marya D ^b,c   Kan, Jason ^d   Hoffman, Justin ^d   Micek, Scott T ^d   Kollef, Marin H ^e  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b EviMed Research Group LLC   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFEPIME; CEFTRIAXONE; MOXIFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIA; SURVIVAL;

EID: 84878769015     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002898     Document Type: Article

References (26)

1. Niederman M. In the clinic. Community-acquired pneumonia. Ann Intern Med 2009;151:ITC4-2-14.
2. Zilberberg MD, Shorr AF. Healthcare-associated pneumonia: the state of evidence to date. Curr Opin Pulm Med 2011;17:142-7.
3. Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54:193-8.
4. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51. (Pubitemid 41539937)
5. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62. (Pubitemid 43062645)
6. Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010;137:1283-8.
7. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;17:388-416.
8. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010;50:202-9.
9. Kovaleva A, Remmelts HH, Rijkers GT, et al. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother 2012;67:530-40.
10. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:612-20.
11. Tessmer A, Welte T, Martus P, et al. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009;63:1025-33.
12. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72. (Pubitemid 46290553)
13. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
15. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-73. (Pubitemid 46280407)
16. Asadi L, Eurich DT, Gamble JM, et al. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect 2012. doi:10.1111/j.1469-0691.2012.03783.x. [Epub ahead of print] PubMed PMID: 22404691.
17. Wilson BZ, Anzueto A, Restrepo MI, et al. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community acquired pneumonia. Crit Care Med 2012. [Epub ahead of print] PubMed PMID: 22622401.
18. Skalsky K, Yahav D, Lador A, et al. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect 2012. doi:10.1111/j.1469-0691.2012.03838.x. [Epub ahead of print] PubMed PMID: 22489673.
19. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012. [Epub ahead of print] PubMed PMID: 22511553.
20. Koch CC, Esteban DJ, Chin AC, et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother 2000;46:19-26. (Pubitemid 30466191)
21. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-70. (Pubitemid 44330550)
22. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007;60:1155-8. (Pubitemid 47617770)
23. Lin SJ, Yan DC, Lee WI, et al. Effect of azithromycin on natural killer cell function. Int Immunopharmacol 2012;13:8-14.
24. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-48.
25. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306-11. (Pubitemid 40463352)
26. FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. http://www.fda.gov/Drugs/Drugsafety/ucm304372.htm (accessed 12 Jul 2012).